Showcase

公司名稱 Company Name

啓源生物科技有限公司
Blymphix Biotech Limited
公司簡介 Company Background
啓源生科將致力於創新藥的開發，包括抗體、小分子，抗癌、自免，等藥物的開發。從源頭進行扎實的科研，致力於用領先科技手段顯著提高成藥性，讓藥物開發更快速、精準、優質，更多的人能用上更好的藥物。
Blymphix Biotech will focus on the development of innovative drugs, including antibodies, small molecules, and treatments for cancer and autoimmune diseases. By conducting rigorous research from the ground up and leveraging the latest technological advancements to significantly enhance candidates’ druggability. We aim to make drug development faster, more precise, and of higher quality, ensuring that more people have access to better medications.
陳列產品之簡介 Description of displayed product
抗體候選藥物將源自免疫細胞人源化小鼠模型中的人類 B 細胞。這將突破以編碼人類抗體的 DNA 取代小鼠抗體的DNA 現有方法。用鼠源B細胞產生抗體，於蛋白質修飾中的糖基化，其與人類存在差異，成藥率低。通過建立M3H7免疫系統人源化小鼠，和AI輔助抗體藥物開發系統，讓人的B細胞在小鼠體內直接產生抗體。
Our anti-cancer antibody will candidate from human B-cell in immune cell humanized mouse model. It is different with current. The current mouse model adopted the methods having human antibody coded DNA instead mouse antibody coded DNA. The main limitation of that is glycosylation in protein modification process compared with human. The different of glycosylation will cause the different 3-D structures in same amino acid sequence (protein) which causes different affinity to same antigen. The successful rate is very low (10-20%) and costly. We will generate the immune cell humanized mouse model which allows human immune cell to grow well and be functional in the mouse. The mouse will loss it immune cells, including matured and functional B-cell, T-cell and NK-cell, instead by human matured and functional immune cells, especially human B-cells. The anti-cancer antibody candidates from human B-cells, there is no glycosylation difference. The affinity is not changed thereafter.
公司產品 Company products